NASDAQ:XENE - Xenon Pharmaceuticals Stock Price, Forecast & News

Xenon Pharmaceuticals trades on the NASDAQ under the ticker symbol "XENE."

Xenon Pharmaceuticals Inc (NASDAQ:XENE) released its quarterly earnings results on Tuesday, November, 5th. The biopharmaceutical company reported ($0.33) earnings per share for the quarter, topping analysts' consensus estimates of ($0.49) by $0.16. The biopharmaceutical company had revenue of $3.50 million for the quarter. View Xenon Pharmaceuticals' Earnings History.

Xenon Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, March 4th 2020. View Earnings Estimates for Xenon Pharmaceuticals.

3 analysts have issued 12-month price targets for Xenon Pharmaceuticals' stock. Their forecasts range from $18.00 to $25.00. On average, they expect Xenon Pharmaceuticals' stock price to reach $21.50 in the next year. This suggests a possible upside of 37.3% from the stock's current price. View Analyst Price Targets for Xenon Pharmaceuticals.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Xenon Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Xenon Pharmaceuticals.

News articles about XENE stock have trended very positive this week, according to InfoTrie Sentiment. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Xenon Pharmaceuticals earned a media sentiment score of 3.9 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the next several days. View News Stories for Xenon Pharmaceuticals.

Xenon Pharmaceuticals saw a decrease in short interest during the month of December. As of December 31st, there was short interest totalling 429,800 shares, a decrease of 24.4% from the December 15th total of 568,400 shares. Based on an average trading volume of 174,100 shares, the short-interest ratio is currently 2.5 days. Currently, 2.1% of the company's stock are sold short. View Xenon Pharmaceuticals' Current Options Chain.

Some companies that are related to Xenon Pharmaceuticals include Arvinas (ARVN), Tricida (TCDA), Ligand Pharmaceuticals (LGND), Alder Biopharmaceuticals (ALDR), Amneal Pharmaceuticals (AMRX), Constellation Pharmaceuticals (CNST), Corcept Therapeutics (CORT), Esperion Therapeutics (ESPR), Nabriva Therapeutics (NBRV), Theravance Biopharma (TBPH), Innoviva (INVA), Endo International (ENDP), Intra-Cellular Therapies (ITCI), BELLUS Health (BLUSF) and Y-mAbs Therapeutics (YMAB).

Based on aggregate information from My MarketBeat watchlists, some companies that other Xenon Pharmaceuticals investors own include Corbus Pharmaceuticals (CRBP), Viking Therapeutics (VKTX), Fate Therapeutics (FATE), Nektar Therapeutics (NKTR), Novavax (NVAX), Progenics Pharmaceuticals (PGNX), Exelixis (EXEL), Galmed Pharmaceuticals (GLMD), Karyopharm Therapeutics (KPTI) and Sucampo Pharmaceuticals (SCMP).

Shares of XENE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of XENE stock can currently be purchased for approximately $15.66.

Xenon Pharmaceuticals has a market capitalization of $405.12 million and generates $310,000.00 in revenue each year. The biopharmaceutical company earns $-34,500,000.00 in net income (profit) each year or ($1.33) on an earnings per share basis. Xenon Pharmaceuticals employs 89 workers across the globe.View Additional Information About Xenon Pharmaceuticals.

The official website for Xenon Pharmaceuticals is http://www.xenon-pharma.com/.

Xenon Pharmaceuticals' mailing address is 200 - 3650 GILMORE WAY, BURNABY A1, V5G 48W. The biopharmaceutical company can be reached via phone at 604-484-3300 or via email at [email protected]